5 research outputs found
Novel PITX2 Homeodomain-Contained Mutations from ATRIAL Fibrillation Patients Deteriorate Calcium Homeostasis
Atrial fibrillation (AF) is the most common cardiac arrhythmia in the human population, with an estimated incidence of 1¿2% in young adults but increasing to more than 10% in 80+ years patients. Pituitary Homeobox 2, Paired Like Homeodomain 2 (PITX2c) loss-of-function in mice revealed that this homeodomain (HD)-containing transcription factor plays a pivotal role in atrial electrophysiology and calcium homeostasis and point to PITX2 as a candidate gene for AF. To address this issue, we recruited 31 AF patients for genetic analyses of both the known risk alleles and PITX2c open reading frame (ORF) re-sequencing. We found two-point mutations in the homedomain of PITX2 and three other variants in the 5¿untranslated region. A 65 years old male patient without 4q25 risk variants but with recurrent AF displayed two distinct HD-mutations, NM_000325.5:c.309G>C (Gln103His) and NM_000325.5:c.370G>A (Glu124Lys), which both resulted in a change within a highly conserved amino acid position. To address the functional impact of the PITX2 HD mutations, we generated plasmid constructs with mutated version of each nucleotide variant (MD4 and MD5, respectively) as well as a dominant negative control construct in which the PITX2 HD was lacking (DN). Functional analyses demonstrated PITX2c MD4 and PITX2c MD5 decreased Nppa-luciferase transactivation by 50% and 40%, respectively, similar to the PITX2c DN (50%), while Shox2 promoter repression was also impaired. Co-transactivation with other cardiac-enriched co-factors, such as Gata4 and Nkx2.5, was similarly impaired, further supporting the pivotal role of these mutations for correct PITX2c function. Furthermore, when expressed in HL1 cardiomyocyte cultures, the PITX2 mutants impaired endogenous expression of calcium regulatory proteins and induced alterations in sarcoplasmic reticulum (SR) calcium accumulation. This favored alternating and irregular calcium transient amplitudes, causing deterioration of the beat-to-beat stability upon elevation of the stimulation frequency. Overall this data demonstrate that these novel PITX2c HD-mutations might be causative of atrial fibrillation in the carrier.This work was supported by grants from The Spanish Ministry of Science Innovation and
Universities [SAF2017-88019-C3-1-R] to L.H.-M. V.J.-S. was employed by CIBERCV [RD12/0042/0002]
grant. Work was also supported by a PhD scholarship [FPU18/01250] to S.C., and partially funded
by grants from Generalitat de Catalunya [SGR2017-1769] and Fundació Marato TV3 [20152030] to
L.H.-M., a translational CNIC grant [2009/08] to D.F., R.C. and L.H.-M. and a grant-in-aid from the
Junta de Andalucia Regional Council to D.F. and A.A. [CTS-446]
Cardiac conduction system anomalies and sudden cardiac death: insights from murine models
The cardiac conduction system (CCS) is a series of specialized tissues in the heart responsible for the initiation and co-ordination of the heartbeat. Alterations in the CCS, especially the His-Purkinje system, have been identified as an important player in the generation of lethal arrhythmias. Unstable arrhythmias secondary to channelopathies highly increase the risk of sudden cardiac death (SCD). Sudden cardiac death is a major contributor to mortality in industrialized nations, and most cases of SCD in the young are related to inherited ion channel diseases. In this review we examine how murine transgenic models have contributed to understanding that a broad variety of cardiac arrhythmias involve the cardiac specialized conduction system and may lead to sudden cardiac death
Modulation of myogenic differentiation in a human rhabdomyosarcoma cell line by a new derivative of 5-fluorouracil (QF-3602)
The in vitro study of mechanisms involved in drug-induced maturation has made it possible to use differentiation-based therapy in clinical practice. The goal of this new therapy is the development of specific agents to induce cancer cells to stop proliferating and express characteristics of normal cells. Recently, by structural modifications of 5-fluorouracil (5-FU), we synthesized a new pyrimidine acyclonucleoside-like compound, 1-{[3-(3-chloro-2-hydroxypropoxy)-1-methoxy]propyl}-5-fluorouracil (QF-3602), which showed in rhabdomyosarcoma cells a low toxicity and time-dependent growth inhibition. In this work, we compared the degree of myogenic differentiation of RD rhabdomyosarcoma (RMS) cells after treatment with QF-3602 and 5-FU. Scanning and transmission electron microscopy (SEM and TEM) and immunocytochemical analyses showed that QF-3602 induced the appearance of myofilaments along the myotube-like giant RD cells, an increase in fibronectin and a decrease in vimentin expression. In contrast, only minor changes were observed with 5-FU. Moreover, polymerase chain reaction (PCR) analyses showed that QF-3602 did not induce overexpression of the mdr 1 gene, a resistance mechanism that frequently appears in classical cytotoxic therapy in these tumors. Compounds obtained by structural modifications of 5-FU may be useful in differentiation therapy as a new approach to the treatment of RMS
Long-range regulatory interactions at the 4q25 atrial fibrillation risk locus involve PITX2c and ENPEP
Background: Recent genome-wide association studies have uncovered
genomic loci that underlie an increased risk for atrial fibrillation,
the major cardiac arrhythmia in humans. The most significant locus is
located in a gene desert at 4q25, approximately 170 kilobases upstream
of PITX2, which codes for a transcription factor involved in embryonic
left-right asymmetry and cardiac development. However, how this genomic
region functionally and structurally relates to PITX2 and atrial
fibrillation is unknown.
Results: To characterise its function, we tested genomic fragments from
4q25 for transcriptional activity in a mouse atrial cardiomyocyte cell
line and in transgenic mouse embryos, identifying a non-tissue-specific
potentiator regulatory element. Chromosome conformation capture revealed
that this region physically interacts with the promoter of the cardiac
specific isoform of Pitx2. Surprisingly, this regulatory region also
interacts with the promoter of the next neighbouring gene, Enpep, which
we show to be expressed in regions of the developing mouse heart
essential for cardiac electrical activity.
Conclusions: Our data suggest that de-regulation of both PITX2 and ENPEP
could contribute to an increased risk of atrial fibrillation in carriers
of disease-associated variants, and show the challenges that we face in
the functional analysis of genome-wide disease associations.We thank Miguel Torres and members of the Manzanares lab for support and
comments; Christine Mummery, Jose Luis de la Pompa and Joaquin
Rodriguez-Leon for reagents; the CNIC Transgenic Unit for generation of
embryos; Stuart Pocock for statistical advice; and Simon Bartlett for
English editing. This study was funded by the CNIC Translational Grant
Programme (CNIC-08-2009 to MM and DF), the Spanish Ministerio de
Economia y Competitividad (grants BFU2011-23083 to MM, BFU2013-41322-P
to JLGS, BFU2012-38111 to AA, and CSD2007-00008 to JLGS and MM), the
Comunidad Autonoma de Madrid (grant CELLDD-CM to MM), and the Andalusian
Government (grant BIO-396 to JLGS). The CNIC is supported by the Spanish
Ministerio de Economia y Competitividad and the Pro-CNIC Foundation.S
miR-106b is a novel target to promote muscle regeneration and restore satellite stem cell function in injured Duchenne dystrophic muscle.
Satellite cells (SCs), muscle stem cells, display functional heterogeneity, and dramatic changes linked to their regenerative capabilities are associated with muscle-wasting diseases. SC behavior is related to endogenous expression of the myogenic transcription factor MYF5 and the propensity to enter into the cell cycle. Here, we report a role for miR-106b reinforcing MYF5 inhibition and blocking cell proliferation in a subset of highly quiescent SC population. miR-106b down-regulation occurs during SC activation and is required for proper muscle repair. In addition, miR-106b is increased in dystrophic mice, and intramuscular injection of antimiR in injured mdx mice enhances muscle regeneration promoting transcriptional changes involved in skeletal muscle differentiation. miR-106b inhibition promotes the engraftment of human muscle stem cells. Furthermore, miR-106b is also high in human dystrophic muscle stem cells and its inhibition improves intrinsic proliferative defects and increases their myogenic potential. This study demonstrates that miR-106b is an important modulator of SC quiescence, and that miR-106b may be a new target to develop therapeutic strategies to promote muscle regeneration improving the regenerative capabilities of injured dystrophic muscle